https://doi.org/10.55788/53b910f5
Dr He and colleagues compared the effectiveness of an intensive BP intervention to usual care on the risk reduction of dementia in patients with hypertension in a cluster-randomised trial [1]. The 33,995 participants with hypertension from 326 rural Chinese villages were randomised 1:1. The experimental BP intervention included doctor-initiated titration of anti-hypertensive drugs, the delivery of discounted and free medications to patients, lifestyle interventions, education on BP monitoring, and medication adherence instructions. The primary outcome was all-cause dementia at 48 months.
“In the usual-care arm, the systolic BP had dropped by a mean of 7.2 mmHg, and this measure was by a mean of 29.2 mmHg in the experimental arm,” said Dr He. For diastolic BP, the corresponding rates were -6.1 mmHg and -15.4 mmHg. In addition, 67.7% of the participants in the intervention arm were normotensive at 48 months compared with 15.0% in the usual-care arm (P<0.0001). Not surprisingly, those in the intervention arm were on a higher number of anti-hypertensive agents (mean 3.0 vs 1.2; P<0.0001). “Importantly, the primary outcome was met, with an annual rate of 1.12% of all-cause dementia in the intervention arm and a rate of 1.31% in the usual-care arm, representing a 15% reduction,” said Dr He (RR 0.85; 95% CI 0.76–0.95; P=0.0035).
“This is the first definitive evidence from a randomised-controlled trial showing the effect of a BP-lowering intervention on dementia risk reduction,” Dr Daniel Jones (University of Mississippi, MS, USA) congratulated the study authors. “Next, we have to investigate whether intensive BP reduction decreases the risk for all forms of dementia. Also, the role of BP in the pathophysiology of Alzheimer's disease, vascular dementia, and other forms of dementia needs to be studied.” Finally, Dr Jones expressed that it would be interesting to investigate whether earlier intervention offers more protection.
- He J, et al. Effectiveness of blood pressure lowering intervention on risk of total dementia among patients with hypertension: a cluster-randomised effectiveness trial. LB04, AHA Scientific Sessions 2023, 11–13 November, Philadelphia, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Post-partum intervention lowers BP after hypertensive pregnancy Next Article
Sodium intake and blood pressure: new insights »
« Post-partum intervention lowers BP after hypertensive pregnancy Next Article
Sodium intake and blood pressure: new insights »
Table of Contents: AHA 2023
Featured articles
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Hot Topics in CAD/PAD
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
ORBITA-2 confirms PCI effective for symptom relief in patients with stable angina
Nicotinamide riboside shows promising trend for walking function in PAD
Pemafibrate reduces microvascular complications of PAD and T2D
Dapagliflozin improves cardiometabolic outcomes in myocardial infarction
Optimising Hypertension Outcomes
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension
Sodium intake and blood pressure: new insights
Post-partum intervention lowers BP after hypertensive pregnancy
Biannual zilebesiran associated with substantial BP reductions
Future of Lipid-Lowering Therapies
Encouraging data for lepodisiran as Lp(a) lowering therapy
Gene editing may change the treatment landscape of hypercholesterolaemia
REPRIEVE: Mechanisms behind MACE reduction in HIV population on pitavastatin
Recaticimab may offer a solution for uncontrolled hypercholesterolaemia
Atrial Fibrillation and Sudden Cardiac Death
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Liraglutide may improve post-ablation outcomes in obese patients with AF
Single or dual cardioversion in patients with obesity and AF?
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator
Sudden cardiac death in athletes: incidence, causes, and trends over 20 years
Miscellaneous Trials
Successful results for semaglutide in the highly anticipated SELECT trial
Can a walking intervention improve functional status and quality of life in HFrEF?
Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com